How do M&A activities typically unfold in the pharma industry in the ASEAN region?
CONSULTANT & EXPORT HEAD AT FMCG COMPANY
“M&A activities in the pharma industry are dependent on the purpose of the parties. Often, the determining factor is the ease of expanding the business in the target region because one of the parties already exists there. If this is the case, they already have manufacturing facilities and registration capacity, as well as human capital. All of these make it easier for the company to make a new beginning, especially in countries with strict regulations. M&A will also be beneficial for both parties in the pharma industry if they can create or deliver the new molecule, or alternatively, a new product delivery system.”